Between November 2025 and April 2026 the self-pay price of the category dropped from roughly $1,100 to $1,350 a month down to the $300s. If your program earned on the spread, the spread is gone.
Key Takeaways
- The White House announced in November 2025 that Wegovy would fall from a stated $1,350 a month to $350 through TrumpRx, and Zepbound from $1,086 to an average of $346. Novo’s April 2026 self-pay guide lists Wegovy at $349 standard.
- Lilly reported fourth-quarter 2025 U.S. revenue up 43 percent on a 50 percent volume increase partially offset by a 7 percent decrease in realized prices. Volume is compounding while price deflates.
- Manufacturer direct channels route the patient around your dispensary. But TrumpRx self-pay pricing explicitly excludes anyone with Medicare, Medicaid, VA, DOD or TRICARE coverage – which is where navigation work still has value.
- Rebuild the model on three numbers: revenue per enrolled patient per month, fully loaded cost to serve per patient month, and median months enrolled. Drug pass-through belongs on its own line at its own margin.
On November 6, 2025, the White House announced pricing agreements with Novo Nordisk and Eli Lilly. Wegovy would fall from a stated $1,350 a month to $350 through the federal TrumpRx channel. Zepbound would fall from $1,086 to an average of $346. Three weeks later, on December 1, Lilly cut its own self-pay vial prices to $299 for 2.5 mg, $399 for 5 mg, and $449 for the 7.5 mg through 15 mg doses. By April 2026, Novo Nordisk’s published self-pay price guide listed Wegovy at $349 a month standard, with a $199 introductory price on a new patient’s first two fills. In roughly eighteen months the cash price of this category fell by about two thirds.
If your program’s margin came from the spread between what you paid for the drug and what the patient paid you, that margin is largely gone, and the manufacturers have told you it is not coming back. Lilly’s fourth-quarter 2025 results reported U.S. revenue up 43 percent on a 50 percent volume increase “partially offset by a 7 percent decrease in realized prices,” attributed to Zepbound and Mounjaro. Novo Nordisk guided 2026 adjusted sales growth to negative 5 to negative 13 percent at constant exchange rates and named the cause directly: lower realized prices, including the most-favored-nation agreement in the United States. Two companies with every incentive to project strength are telling their investors that price is falling.
Demand, meanwhile, has not weakened at all. CDC’s most recent national estimate puts adult obesity at 40.3 percent. Zepbound alone booked $13.5 billion in 2025 revenue, up 175 percent year over year. Volume is compounding while price deflates – which is exactly the condition under which a distributor gets squeezed and a service business gets bigger. The question for a practice owner is no longer whether to run a GLP-1 program. It is what, precisely, the patient is paying you for.
The Drug Is Not Your Product
A practice that buys drug and resells it at a markup is operating as a distributor. Distribution is a legitimate business, but it is a low-margin one, and in this category the price is set by two manufacturers and, for a growing share of volume, by the federal government. Worse, both manufacturers have built direct-to-patient channels – NovoCare Pharmacy, LillyDirect, and now TrumpRx.gov – that route the patient around you entirely. You cannot win a price war against your own supplier’s storefront, and you should stop trying.
There are two structural gaps in those direct channels, and both are worth money. The first is eligibility. The TrumpRx Wegovy page states plainly that the self-pay price is for self-pay patients only and is not available to anyone with Medicare, Medicare Part D, Medicare Advantage, VA, DOD, TRICARE, or Medicaid coverage. A large share of the population most affected by obesity is therefore locked out of the headline number and lands instead in a maze of formulary exclusions, prior authorizations and demonstration programs. Sorting that out for a patient is real work with a real cost, and it is the kind of work patients will pay a program fee to have done well.
The second gap is administrative and it has a dollar figure attached. Lilly’s December 2025 release specifies that the $449 price for the 7.5 mg through 15 mg vials applies only on the first fill and when prescriptions are refilled within 45 days of the previous delivery. Miss that window and 12.5 mg reverts to $849, 15 mg to $1,049. In most practices a missed refill date is not a clinical event and nobody owns it. Here it is a $400 to $600 event for the patient and a churn event for you. A refill-window worklist is not glamorous operations. It is one of the highest-return process changes available in this specialty right now.
If the drug’s price falls by two thirds and your program price falls with it, you were selling the drug. If your price holds, you were selling the program.
Rebuild the Model on the Visit, Not the Vial
Stop looking at gross revenue and rebuild around three numbers.
- Revenue per enrolled patient per month. Program fee, visit revenue, insurance collections where applicable, and lab margin if you own the draw. Exclude drug pass-through entirely, or carry it on a separate line at its own margin. Blending the two hides the deflation until the year closes and the P and L looks nothing like the plan.
- Fully loaded cost to serve, per patient per month. Provider minutes at a loaded hourly rate, medical assistant and front desk minutes, labs, platform and messaging seats, payment processing, and prior authorization labor. That last item is bigger than most owners assume. The AMA’s 2025 prior authorization survey found practices completing 40 prior authorizations per physician per week and spending 13 hours a week on them.
- Median months enrolled. This is the multiplier on everything above, and in this specialty it is the single most sensitive input in the model. It belongs in your pricing spreadsheet, not in a separate conversation about marketing.
Revenue per patient month minus cost to serve, multiplied by median months enrolled, gives contribution per enrolled patient. Set that against fully loaded acquisition cost and you know whether the program is a business. Most owners running these programs have never computed it, because the practice management system reports revenue by CPT code and reports the cash program by nothing useful at all.
Where the Margin Actually Leaks
When we open the books on a medical weight loss program that feels busy and thin, the leaks cluster. Membership pricing that was benchmarked against the old drug price and never revisited, so the program fee fell alongside a drug cost the practice no longer even carries. Unlimited or loosely defined follow-up visits, which convert a fixed monthly fee into an uncapped clinical liability. Refill administration and message triage absorbed by clinical staff and never priced. Discounting at intake to close the sale, which permanently resets the patient’s price anchor. And acquisition spend running without attribution, so nobody can say what a patient costs to get, let alone whether they are worth it.
None of these are exotic. All of them are visible once revenue is segmented by program component rather than reported as one deposit. That is why the first deliverable in this kind of engagement is usually a rebuilt revenue map rather than a pricing recommendation. You cannot reprice what you cannot see.
From the Field
A single-site medical weight loss practice in the Mountain West, roughly 550 active patients on a flat monthly membership that had originally been priced to include a drug the practice stopped supplying in 2025, was watching contribution fall every quarter while patient count held steady. Leadership assumed it was a volume problem and wanted to spend more on ads. The financial review found the program fee had been cut twice to “stay competitive” with falling cash drug prices, while cost to serve rose as message volume and refill administration grew. Rather than deliver a pricing memo, our fractional COO engagement segmented revenue into program, visit and lab lines, built a per-patient-per-month contribution model in the practice’s own reporting, rewrote the membership tiers to cap included follow-ups and price beyond them, sat with the front desk for three weeks to rebuild the enrollment conversation and the refill-window worklist, and retrained the medical assistants on message triage. Contribution per enrolled patient improved by a little over 30 percent within two quarters on essentially flat patient volume. Advertising spend did not change.
Advice, Execution, and Which One You Need
Nothing in this article is a secret. A competent consultant will diagnose most of it in a focused engagement and hand you a clear, correct pricing model and an implementation plan. If you have a practice administrator with unclaimed hours and the authority to change scripts, tiers and workflows, that is very often the better value, and it is what we will recommend on the call. Consulting is not a lesser product. It is a different distribution of the work.
The problem in most medical weight loss practices is not the plan. It is that the person who would execute it is also running intake, chasing prior authorizations and answering the message queue. A plan requiring sixty hours of focused attention does not get executed by someone with zero unclaimed hours, no matter how good the plan is. That is what a fractional executive is for: the same analysis, then someone working inside your systems – rewriting the membership tiers in your billing platform, sitting with the front desk through the enrollment script, building the refill worklist, running the monthly numbers with your administrator – until the metric moves and the habit sticks.
Be a careful buyer. “Fractional executive” is an unregulated label and some firms sell ordinary consulting under it. The test is simple and you should ask it directly: will this person be working in our systems with our staff, or delivering to us and leaving us to deploy it? Both are honest services. Only one of them is fractional executive work, and you should know which you are buying before you sign.
Sources
- The White House, Fact Sheet: Most-Favored-Nation Pricing Agreements with Novo Nordisk and Eli Lilly (November 6, 2025) — https://www.whitehouse.gov/fact-sheets/2025/11/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients/
- Eli Lilly, Lilly lowers the price of Zepbound single-dose vials (December 1, 2025) — https://investor.lilly.com/news-releases/news-release-details/lilly-lowers-price-zepboundr-tirzepatide-single-dose-vials
- Eli Lilly, Fourth Quarter 2025 Financial Results (February 4, 2026) — https://investor.lilly.com/news-releases/news-release-details/lilly-reports-fourth-quarter-2025-financial-results-and-provides
- Novo Nordisk, Annual Report 2025 – Financial Performance and Outlook — https://annualreport.novonordisk.com/2025/strategic-aspirations/financial-performance.html
- TrumpRx.gov, Wegovy Pen product and eligibility page — https://trumprx.gov/p/wegovy
- CDC/NCHS, Obesity and Severe Obesity Prevalence in Adults: United States, August 2021-August 2023 (Data Brief No. 508) — https://www.cdc.gov/nchs/products/databriefs/db508.htm
More in the Medical Weight Loss Series
- Three Compliance Fronts That Can End a Weight Loss Practice – and None of Them Are Clinical — the compounding, telehealth and advertising rules that moved under this specialty between 2024 and 2026.
- Attrition, Not Acquisition, Decides Your P and L — why median months enrolled is the most sensitive number in a weight loss program.
- Insurance or Cash in Obesity Medicine: Run the Numbers First — what the coverage landscape actually supports, and how hybrid models are built.
- Scaling With APPs and Second Sites: What Actually Breaks — what breaks when you add a provider or a second location, and the order to fix it in.